In the latter case, despite a good prognosis of PR-positive breast cancer patients and a better response to endocrine therapy, with a 5-year overall survival superior to 90%, resistance occurs and has driven extensive studies on PR pathway signaling [5]. Here, PGR is linked to breast carcinoma.